SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 7.2% Passive Stake in Teva Pharmaceutical Industries Ltd.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 7.2% of Teva Pharmaceutical Industries Ltd.'s common stock as of December 31, 2024.

Summary

• FMR LLC and Abigail P. Johnson filed an Amendment No. 1 to Schedule 13G concerning their beneficial ownership of common stock in Teva Pharmaceutical Industries Ltd.
• As of December 31, 2024, the aggregate amount beneficially owned by FMR LLC and Abigail P. Johnson is 81,983,228.79 shares.
• This ownership represents 7.2% of the total outstanding common stock of Teva Pharmaceutical Industries Ltd.
• FMR LLC holds sole voting power over 76,829,800.65 shares and sole dispositive power over 81,983,228.79 shares.
• Abigail P. Johnson holds sole dispositive power over 81,983,228.79 shares.
• Neither FMR LLC nor Abigail P. Johnson reported any shared voting or shared dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• FMR LLC is classified as a parent holding company or control person (HC), and Abigail P. Johnson is classified as an individual (IN).
• Subsidiaries of FMR LLC identified as beneficially owning shares include FIAM LLC (Investment Adviser), Fidelity Institutional Asset Management Trust Company (Bank), Fidelity Management & Research Company LLC (Investment Adviser), Fidelity Management Trust Company (Bank), and Strategic Advisers LLC (Investment Adviser).
• Fidelity Management & Research Company LLC beneficially owns 5% or greater of the outstanding shares of Teva Pharmaceutical Industries Ltd.
• Members of the Johnson family, including Abigail P. Johnson, are the predominant owners of Series B voting common shares of FMR LLC, representing 49% of the voting power, and have a voting agreement that may deem them a controlling group with respect to FMR LLC.

Sentiment

Score: 5

Explanation: The document is a factual, routine regulatory filing disclosing beneficial ownership, with no inherent positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• The disclosure of a significant 7.2% passive stake by a major investment firm like FMR LLC could be viewed by some investors as a positive signal of confidence in Teva Pharmaceutical Industries Ltd.

Negatives

• The document, being a beneficial ownership filing, does not contain information regarding the operational or financial performance of Teva Pharmaceutical Industries Ltd. that would indicate negatives.

Risks

• The document does not detail specific risks related to Teva Pharmaceutical Industries Ltd.'s business operations or financial health, as it is a beneficial ownership disclosure.

Future Outlook

The Schedule 13G filing does not provide any forward-looking statements or guidance regarding Teva Pharmaceutical Industries Ltd.'s future performance or outlook.

Management Comments

• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This Schedule 13G filing is a routine disclosure of a passive investment stake and does not provide specific analysis of broader industry trends or competitive landscape within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant passive ownership stake in Teva Pharmaceutical Industries Ltd. by FMR LLC and Abigail P. Johnson.

Next Steps

• The document implies continued passive holding of the shares by FMR LLC and Abigail P. Johnson, with no specific future actions or milestones for Teva Pharmaceutical Industries Ltd. mentioned by the reporting persons.

Key Dates

Keywords

Teva Pharmaceutical Industries Ltd, FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, pharmaceutical, investment, passive stake